$美鼎生物(VIVO)$ Form 10-Q

Consolidated revenues for the second quarter of fiscal 2020 totaled $57,296, an increase of 14% compared to the second quarter of fiscal 2019 (15% increase on a constant-currency basis).

Revenues for the Diagnostics segment for the second quarter of fiscal 2020 increased 4% compared to the second quarter of fiscal 2019 (5% increase on a constant-currency basis), comprised of a 2% increase in molecular assay products and a 5% increase in immunoassay and blood chemistry assay products. As previously noted, the

COVID-19 pandemic dramatically slowed the placement of our molecular assay products during the quarter, resulting in 35 Revogene® systems being installed during the second quarter of fiscal 2020 and a total Revogene system install base of 148 systems as of March 31, 2020. With a 114% increase in molecular reagents products and a 5% decrease in immunological reagents products, revenues for our Life Science segment increased 33% during the second quarter of fiscal 2020 compared to the second quarter of fiscal 2019. On a constant-currency basis, revenues for the Life Science segment increased 34%. Life Science revenues reflect a significant increase in the sales of key molecular components such as RNA master mixes and deoxyribonucleotide triphosphates (“dNTPs”) to diagnostic test manufacturers for use in

COVID-19 related tests, including a fourfold increase in revenue from sales into China.